Jeffrey M. Conroy
Research Subjects
Jeffrey M. Conroy has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
- Carol Farhangfar
Department of Translational Research, Levine Cancer Institute, Atrium Health, Charlotte, NC
47 shared publications - David Neil Hayes
University of Tennessee Health Science Center UTHSC Center for Cancer Research Memphis, TN
47 shared publications - Farhang Farhangfar
Levine Cancer Institute, Atrium Health , Charlotte, NC
47 shared publications - Gregory M. Mayhew
GeneCentric Therapeutics, Inc., Durham, North Carolina
47 shared publications - James M. Davison
GeneCentric Therapeutics, Inc., Durham, North Carolina
47 shared publications - Joel R. Eisner
GeneCentric Therapeutics, Inc., Durham, North Carolina
47 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary table 1 shows baseline characteristics (sex and age) as well as breakdown of malignancy types in patients included in analysis
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary table 1 shows baseline characteristics (sex and age) as well as breakdown of malignancy types in patients included in analysis
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary table 2 exploring the relationship of median overall survival with high GITR and high GITR plus low/moderate GITR-L RNA expression in patients who received immunotherapy via COX analysis failed to reveal a relationship between survival and high GITR as well as high GITR plus low/moderate GITR-L expression on univariate analysis, but multivariate analysis implied better median overall survival in patients with high GITR plus low/moderate GITR-L expression when accounting for the RNA expression of other immunomodulatory proteins on multivariate analysis
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary table 2 exploring the relationship of median overall survival with high GITR and high GITR plus low/moderate GITR-L RNA expression in patients who received immunotherapy via COX analysis failed to reveal a relationship between survival and high GITR as well as high GITR plus low/moderate GITR-L expression on univariate analysis, but multivariate analysis implied better median overall survival in patients with high GITR plus low/moderate GITR-L expression when accounting for the RNA expression of other immunomodulatory proteins on multivariate analysis
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary figure 1 showing no PFS benefit in patients who received IO regardless of GITR and GITR-L levels
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary figure 1 showing no PFS benefit in patients who received IO regardless of GITR and GITR-L levels
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 Legend from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary figure 1 showed no preferential PFS benefit in patients who were either high GITR or high GITR plus GITR-L low/moderate who received immunotherapy
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 Legend from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Supplementary figure 1 showed no preferential PFS benefit in patients who were either high GITR or high GITR plus GITR-L low/moderate who received immunotherapy
- 4 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (11) , 1959-1969
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.
- 4 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (11) , 1959-1969
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy
Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
RNA Sequencing Quality Control Criteria
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
RNA Sequencing Quality Control Criteria
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression of Genes Associated with Antifolate (Pemetrexed) Activity by LUAD Subtype.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Expression of Genes Associated with Antifolate (Pemetrexed) Activity by LUAD Subtype.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Relationship of the expression of individual genes (ATIC, GART, DHFR, MTHFD1L or TYMS) with survival.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
Relationship of the expression of individual genes (ATIC, GART, DHFR, MTHFD1L or TYMS) with survival.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
48 genes included in the new LUAD nearest centroid classifier and associated AF-PRS signature.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
48 genes included in the new LUAD nearest centroid classifier and associated AF-PRS signature.